Trial Profile
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms DANNOAC-VTE
- 05 Jul 2023 Status changed from not yet recruiting to recruiting.
- 02 Apr 2023 Planned End Date changed from 31 Mar 2020 to 31 Mar 2029.
- 02 Apr 2023 Planned primary completion date changed from 31 Mar 2020 to 31 Mar 2027.